Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 50

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 50
---
.

We may offer and sell these securities to or through
one or more underwriters, dealers or agents, or directly to purchasers on a continuous or delayed basis. We reserve the sole right to
accept, and together with any underwriters, dealers and agents, reserve the right to reject, in whole or in part, any proposed purchase
of securities. The names of any underwriters, dealers or agents involved in the sale of any securities, the specific manner in which they
may be offered and any applicable commissions or discounts will be set forth in the prospectus supplement covering the sales of those
securities.

We elected to be taxed as a real estate investment
trust (“REIT”) for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2016. To assist us
in complying with certain U.S. federal income tax requirements applicable to REITs, among other purposes, our charter generally limits
beneficial and constructive ownership by any person to no more than 9.8% in value or in number of shares, whichever is more restrictive,
of the outstanding shares of any class or series of our capital stock. In addition, our charter contains various other restrictions on
the ownership and transfer of our common stock. See “Description of Capital Stock — Restrictions on Ownership and Transfer.”

Our common stock is listed on the New York Stock
Exchange, or the NYSE, under the symbol “GMRE.” Our 7.50% Series A Cumulative Redeemable Preferred Stock is listed on the
NYSE under the symbol “GMRE PrA,” The last reported sale price of our common stock on the NYSE on February 28, 2024 was $8.76
per share. We have not yet determined whether any of the other securities that may be offered by this prospectus will be listed on any
exchange, inter-dealer quotation system or over-the-counter system. If we decide to seek a listing for any of those securities, that will
be disclosed in a prospectus supplement.

Investing in our securities involves risks. Before making a decision to invest in our securities, you should carefully consider the risks described under the section entitled “Risk Factors” on page 6 of this prospectus and included in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed by us with the Securities and Exchange Commission, including any risks described in any accompanying prospectus supplement.

Neither the U.S. Securities and Exchange